Demographic and clinical differences between idiopathic and scleroderma-related pulmonary arterial hypertension: Russian National Registry analysis

Demographic and clinical differences between idiopathic and scleroderma-related pulmonary arterial hypertension: Russian National Registry analysis

Pulmonary arterial hypertension associated with systemic sclerosis (SSc-PAH) and idiopathic pulmonary arterial hypertension (IPAH) belong to group I in the clinical classification of PH, but there is evidence for significant differences in their survival due to current therapy. Objective: the object...

Full description

Bibliographic Details
Main Authors:	N N Yudkina, E G Valeeva, I N Taran, E V Nikolaeva, V M Paramonov, I A Kurmukov, Z S Valieva, O A Arkhipova, T V Martynyuk, A V Volkov, E L Nasonov, I E Chazova
Format:	Article
Language:	Russian
Published:	IP Morozov P.V. 2016-06-01
Series:	Системные гипертензии
Subjects:	idiopathic pulmonary hypertension pulmonary hypertension associated with systemic sclerosis the survival rate of patients with pulmonary arterial hypertension
Online Access:	https://syst-hypertension.ru/2075-082X/article/viewFile/29142/pdf

Similar Items

Demographic and clinical differences between idiopathic and scleroderma-related pulmonary arterial hypertension: Russian National Registry analysis
by: Yudkina N.N., et al.
Published: (2016-06-01)

The development of a screening questionnaire to improve the early detection of pulmonary arterial hypertension
by: Z S Valieva, et al.
Published: (2014-12-01)

Features of clinical, functional and hemodynamics profile, medical treatment and prognosis evaluation in patients with inoperable chronic thromboembolic pulmonary hypertension and idiopathic pulmonary arterial hypertension according to the Russian registry
by: I E Chazova, et al.
Published: (2019-09-01)

Pulmonary arterial hypertension in Russia: six-year observation analysis of the National Registry
by: I E Chazova, et al.
Published: (2019-01-01)

Influence of demographic characteristics on the clinical course and results of therapy in patients with precapillary pulmonary hypertension
by: Irina N. Taran, et al.
Published: (2021-03-01)

A clinical case of long-term macitentan therapy in a female patient with idiopathic pulmonary hypertension
by: O A Arkhipova, et al.
Published: (2016-12-01)

Quality of life in patients with idiopathic pulmonary hypertension: the first experience of trimetazidine
by: E G Kuznetsova, et al.
Published: (2017-06-01)

The validation of the questionnaire for the early detection of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
by: Z S Valieva, et al.
Published: (2016-03-01)

The validation of the questionnaire for the early detection of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
by: Valieva Z.S., et al.
Published: (2016-01-01)

Clinical, functional and hemodynamic profile of patients with Eisenmenger syndrome in comparison with the group of idiopathic pulmonary hypertension, features of starting specific therapy choice
by: Svetlana E Gratsianskaya, et al.
Published: (2019-09-01)

INHALED NITRIC OXIDE: CLINICAL EFFECTS AND INFLUENCE ON THE PROFILE OF INFLAMMATORY MARKERS IN PATIENTS WITH IDIOPATHIC PULMONARY HYPERTENSION
by: T. V. Martynyuk, et al.
Published: (2015-12-01)

Impact of bosentan therapy on stress-induced pulmonary hypertension in patients with systemic sclerosis
by: A V Volkov, et al.
Published: (2015-01-01)

PULMONARY HYPERTENSION: DIFFICULT CASE IN CLINICAL PRACTICE
by: D. V. Madeeva, et al.
Published: (2014-07-01)

PULMONARY HYPERTENSION: DIFFICULT CASE IN CLINICAL PRACTICE
by: D. V. Madeeva, et al.
Published: (2014-07-01)

Comparison of the integral indices of the vectorcardiogram with the data of echocardiography in patients with idiopathic and chronic thromboembolic pulmonary hypertension
by: T A Sakhnova, et al.
Published: (2019-03-01)

Quality of life in patients with idiopathic pulmonary hypertension: the first experience of trimetazidine
by: Kuznetsova E.G., et al.
Published: (2017-05-01)

Pulmonary hypertension in Russia: The first results of the national register
by: I E Chazova, et al.
Published: (2014-09-01)

POSSIBILITIES FOR ECHOCARDIOGRAPHIC DETERMINATION OF PULMONARY ARTERY PRESSURE IN PATIENTS WITH SYSTEMIC CONNECTIVE TISSUE DISEASES: DATA OF A RHEUMATOLOGY EXPERT CENTER
by: E. V. Nikolaeva, et al.
Published: (2015-03-01)

Evaluation of effectiveness and safety of the first Russian-manufactured generic bosentan use in patients with pulmonary arterial hypertension
by: O A Arkhipova, et al.
Published: (2018-12-01)

INVESTIGATION OF CENTRAL HEMODYNAMICS VIA RIGHT HEART AND PULMONARY ARTERY CATHETERIZATION IN PATIENTS WITH SYSTEMIC CONNECTIVE TISSUE DISEASES
by: E. V. Nikolaeva, et al.
Published: (2016-02-01)

Recent trends in pulmonary arterial hypertension
by: Rajagopalan Natarajan
Published: (2011-01-01)

Modern view on the place of riociguat in the treatment of pulmonary hypertension
by: Z S Valieva, et al.
Published: (2018-04-01)

New horizons for the use of the second generation of endothelin receptor antagonist macitentan in patients with pulmonary hypertension
by: T V Martynyuk, et al.
Published: (2018-04-01)

Lung transplantation for idiopathic pulmonary arterial hypertension: perioperational features
by: V. N. Poptsov, et al.
Published: (2019-01-01)

SURVIVAL OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION, ASSOCIATED WITH SYSTEMIC SCLEROSIS
by: A V Volkov, et al.
Published: (2012-05-01)

Modern view on the place of riociguat in the treatment of pulmonary hypertension
by: Z.S. Valieva, et al.
Published: (2018-04-01)

Clinical case: combination therapy with iloprost and sildenafil in the treatment of idiopathic pulmonary hypertension
by: I N Zavyrylina, et al.
Published: (2015-06-01)

Endothelin receptor antagonist bosentan role in modern strategy for patients with pulmonary arterial hypertension treatment
by: O A Arkhipova, et al.
Published: (2018-06-01)

Possibilities of using levosimendan in patients with idiopathic pulmonary hypertension
by: T V Martyniuk, et al.
Published: (2012-09-01)

Survival in pulmonary arterial hypertension, associated with connective tissue diseases, treated by sildenafil: results of the prospective study
by: A V Volkov, et al.
Published: (2015-11-01)

New horizons for the use of the second generation of endothelin receptor antagonist macitentan in patients with pulmonary hypertension
by: T.V. Martynyuk, et al.
Published: (2018-04-01)

Exacerbation of idiopathic pulmonary fibrosis
by: S. N. Avdeev, et al.
Published: (2020-03-01)

Endothelin receptor antagonist bosentan role in modern strategy for patients with pulmonary arterial hypertension treatment
by: Arkhipova O.A., et al.
Published: (2018-05-01)

A Comprehensive Review of Current Treatments and Therapies for Idiopathic Pulmonary Arterial Hypertension
by: Danielle Lancaster, et al.
Published: (2017-04-01)

Incidence and Clinical Characteristics of Pulmonary Hypertension in Patients with Idiopathic Pulmonary Fibrosis
by: Wei Yan, et al.
Published: (2015-01-01)

The first Russian experience of sildenafil application in patients with idiopathic pulmonary hypertension
by: Z Kh Dadacheva, et al.
Published: (2015-09-01)

The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat
by: S. E. Gratsianskaya, et al.
Published: (2020-10-01)

Bosentan use in pulmonary arterial hypertension: Russian and foreign experience
by: Z S Valieva, et al.
Published: (2017-08-01)

Clinical guidelines for the diagnosis and treatment of pulmonary hypertension
by: I E Chazova, et al.
Published: (2014-09-01)

Clinical and hemodynamic characteristics and possibilities for therapy in patients with severe (functional class IV) pulmonary arterial hypertension associated with diffuse connective tissue diseases
by: E V Nikolaeva, et al.
Published: (2015-05-01)